Unraveling the Pathogenetic Mechanisms Underlying the Association between Specific Mitochondrial DNA Haplogroups and Parkinson's Disease

Min-Yu Lan,Tsu-Kung Lin,Baiba Lace,Algirdas Utkus,Birute Burnyte,Kristina Grigalioniene,Yu-Han Lin,Inna Inashkina,Chia-Wei Liou
DOI: https://doi.org/10.3390/cells13080694
IF: 6
2024-04-18
Cells
Abstract:Variants of mitochondrial DNA (mtDNA) have been identified as risk factors for the development of Parkinson's disease (PD). However, the underlying pathogenetic mechanisms remain unclear. Cybrid models carrying various genotypes of mtDNA variants were tested for resistance to PD-simulating MPP+ treatment. The most resistant line was selected for transcriptome profiling, revealing specific genes potentially influencing the resistant characteristic. We then conducted protein validation and molecular biological studies to validate the related pathways as the influential factor. Cybrids carrying the W3 mtDNA haplogroup demonstrated the most resistance to the MPP+ treatment. In the transcriptome study, PPP1R15A was identified, while further study noted elevated expressions of the coding protein GADD34 across all cybrids. In the study of GADD34-related mitochondrial unfolding protein response (mtUPR), we found that canonical mtUPR, launched by the phosphate eIF2a, is involved in the resistant characteristic of specific mtDNA to MPP+ treatment. Our study suggests that a lower expression of GADD34 in the late phase of mtUPR may prolong the mtUPR process, thereby benefitting protein homeostasis and facilitating cellular resistance to PD development. We herein demonstrate that GADD34 plays an important role in PD development and should be further investigated as a target for the development of therapies for PD.
cell biology
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to explore the pathological mechanisms between specific mitochondrial DNA (mtDNA) haplogroups and Parkinson's disease (PD). Specifically, researchers constructed cytoplasmic hybrid cells (cybrids) carrying different mtDNA haplogroups and tested the resistance of these cells to MPP+ treatment, which simulates the Parkinson's disease environment. The main objectives of the study include: 1. **Determine the resistance of specific mtDNA haplogroups to MPP+ treatment**: - Screen out the mtDNA haplogroup that is most resistant to MPP+ treatment through cell survival rate detection. 2. **Reveal the gene expression characteristics of resistant cells**: - Conduct transcriptome analysis on the most resistant cells to identify genes that may affect their resistance characteristics. 3. **Verify the functions of related genes and pathways**: - Further confirm the roles of these genes and their related pathways in resisting MPP+ treatment through protein verification and molecular biology experiments. 4. **Explore the role of GADD34 in the mtUPR pathway**: - Pay special attention to the GADD34 protein and its role in the mtUPR pathway to understand how it affects the cell's resistance to the development of Parkinson's disease. ### Research background Parkinson's disease (PD) is a neurodegenerative disease, mainly manifested by the degeneration of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of Lewy bodies in various brain regions. Mitochondrial dysfunction has been widely recognized as one of the important factors in the pathogenesis of PD. mtDNA variations not only affect mitochondrial energy production and free - radical formation, but also are related to the development of PD. There are associations between different mtDNA haplogroups and the susceptibility or resistance to PD, but the specific pathological mechanisms are still unclear. ### Research methods 1. **Cell line construction and culture**: - Use platelets from healthy volunteers with different backgrounds as mtDNA donors and fuse them with osteosarcoma cells (143B rho) with mitochondria removed to construct cybrid cell lines. 2. **Cell survival rate detection**: - Detect the survival rate of cells after treatment with different concentrations of MPP+ by WST - 1 and Alamar Blue methods, and screen out the cell lines that are most resistant and most sensitive to MPP+ treatment. 3. **Transcriptome analysis**: - Conduct RNA sequencing on the most resistant cell line, analyze its gene expression profile, and identify differentially expressed genes (DEGs). 4. **Protein verification**: - Verify the mRNA levels and protein expressions of key genes by real - time quantitative PCR and Western Blot. ### Main findings 1. **Cell survival rate detection**: - Cells carrying the W3 haplogroup showed the strongest resistance to MPP+ treatment, while cells carrying the H11 haplogroup were the most sensitive. 2. **Transcriptome analysis**: - Through transcriptome analysis of the W3 cell line, 86 differentially expressed genes were found, among which the expressions of PPP1R15A, GADD45A and GABARAPL1 were significantly increased. 3. **Protein verification**: - Further verified the expressions of PPP1R15A and GABARAPL1 in multiple cell lines and found that they were significantly up - regulated after MPP+ treatment. 4. **GADD34 and mtUPR pathway**: - The GADD34 protein plays an important role in the mtUPR pathway, and its expression pattern is related to the cell's resistance to MPP+ treatment. The W3 cell line showed lower GADD34 expression in the second stage of mtUPR, which may help to prolong the mtUPR process, thereby enhancing the cell's resistance to PD. ### Conclusion This study reveals that specific mtDNA haplogroups (such as W3) enhance the cell's resistance to MPP+ treatment by regulating the expression of the GADD34 protein in the mtUPR pathway, which may reduce the risk of Parkinson's disease. These findings provide potential targets for the development of new therapies for PD.